CN105481880B - 一种新化合物及其应用 - Google Patents
一种新化合物及其应用 Download PDFInfo
- Publication number
- CN105481880B CN105481880B CN201510868700.7A CN201510868700A CN105481880B CN 105481880 B CN105481880 B CN 105481880B CN 201510868700 A CN201510868700 A CN 201510868700A CN 105481880 B CN105481880 B CN 105481880B
- Authority
- CN
- China
- Prior art keywords
- noval chemical
- compound
- broadleaf plants
- several broadleaf
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 40
- 206010061218 Inflammation Diseases 0.000 abstract description 8
- 230000004054 inflammatory process Effects 0.000 abstract description 8
- 206010028980 Neoplasm Diseases 0.000 abstract description 5
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 238000000605 extraction Methods 0.000 abstract description 4
- 230000000118 anti-neoplastic effect Effects 0.000 abstract description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 238000000926 separation method Methods 0.000 abstract description 2
- 239000002904 solvent Substances 0.000 abstract description 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 241000196324 Embryophyta Species 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- 239000003513 alkali Substances 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229930013930 alkaloid Natural products 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- -1 Alkaloid compound Chemical class 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 240000005062 Hymenocallis littoralis Species 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 230000004856 capillary permeability Effects 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000040710 Chela Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000005100 correlation spectroscopy Methods 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 125000006575 electron-withdrawing group Chemical group 0.000 description 2
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 2
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000004080 punching Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 241000029132 Paronychia Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000009740 moulding (composite fabrication) Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510868700.7A CN105481880B (zh) | 2015-12-01 | 2015-12-01 | 一种新化合物及其应用 |
CN201710354440.0A CN107007595B (zh) | 2015-12-01 | 2015-12-01 | 水鬼蕉新碱a在制备抗炎药物中的应用 |
CN201710354463.1A CN106943396B (zh) | 2015-12-01 | 2015-12-01 | 水鬼蕉新碱a在制备抗肿瘤药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510868700.7A CN105481880B (zh) | 2015-12-01 | 2015-12-01 | 一种新化合物及其应用 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710354440.0A Division CN107007595B (zh) | 2015-12-01 | 2015-12-01 | 水鬼蕉新碱a在制备抗炎药物中的应用 |
CN201710354463.1A Division CN106943396B (zh) | 2015-12-01 | 2015-12-01 | 水鬼蕉新碱a在制备抗肿瘤药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105481880A CN105481880A (zh) | 2016-04-13 |
CN105481880B true CN105481880B (zh) | 2017-07-14 |
Family
ID=55669194
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510868700.7A Active CN105481880B (zh) | 2015-12-01 | 2015-12-01 | 一种新化合物及其应用 |
CN201710354440.0A Active CN107007595B (zh) | 2015-12-01 | 2015-12-01 | 水鬼蕉新碱a在制备抗炎药物中的应用 |
CN201710354463.1A Active CN106943396B (zh) | 2015-12-01 | 2015-12-01 | 水鬼蕉新碱a在制备抗肿瘤药物中的应用 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710354440.0A Active CN107007595B (zh) | 2015-12-01 | 2015-12-01 | 水鬼蕉新碱a在制备抗炎药物中的应用 |
CN201710354463.1A Active CN106943396B (zh) | 2015-12-01 | 2015-12-01 | 水鬼蕉新碱a在制备抗肿瘤药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (3) | CN105481880B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111494368B (zh) * | 2019-04-30 | 2021-02-26 | 黑龙江中医药大学 | 水鬼蕉新碱a在制备防治阿尔茨海默病的药物中的用途 |
CN113730401B (zh) * | 2021-06-23 | 2023-02-17 | 黑龙江中医药大学 | 水鬼蕉新碱a在制备抗菌的药物中的用途 |
CN113713028A (zh) * | 2021-09-18 | 2021-11-30 | 海南鑫开源医药科技有限公司 | 一种具有抑制肿瘤细胞活性作用的组合物及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005039579B4 (de) * | 2005-08-19 | 2022-06-30 | Magforce Ag | Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen |
CN101318966B (zh) * | 2008-04-10 | 2010-12-15 | 中国人民解放军第二军医大学 | 二聚倍半萜类化合物及其制备方法和应用 |
CN101318946B (zh) * | 2008-04-10 | 2010-11-10 | 中国人民解放军第二军医大学 | 化合物二聚兔耳风萜a及其制备方法和应用 |
FR2934266B1 (fr) * | 2008-07-28 | 2010-09-17 | Pf Medicament | Derives azotes de la pancratistatine |
-
2015
- 2015-12-01 CN CN201510868700.7A patent/CN105481880B/zh active Active
- 2015-12-01 CN CN201710354440.0A patent/CN107007595B/zh active Active
- 2015-12-01 CN CN201710354463.1A patent/CN106943396B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN107007595A (zh) | 2017-08-04 |
CN106943396B (zh) | 2018-08-24 |
CN107007595B (zh) | 2019-01-25 |
CN106943396A (zh) | 2017-07-14 |
CN105481880A (zh) | 2016-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101242850A (zh) | 文冠果的提取物和从提取物分离出的化合物的组成,功能和应用,以及它们的制备方法 | |
CN105481880B (zh) | 一种新化合物及其应用 | |
CN109534984A (zh) | 一种利用互花米草制备对香豆酸的方法 | |
CN106008502B (zh) | 马齿苋中骨架生物碱化合物及其提取分离方法 | |
CN106336438B (zh) | 一种琥珀酰芒柄花苷及其在制备心血管疾病药物方面的应用 | |
CN104311623B (zh) | 一种名为油茶皂苷c1和油茶皂苷c2的五环三萜类化合物及其制备方法与应用 | |
CN104586945A (zh) | 啤酒花总黄酮提取物、制备方法及其作为制备预防和治疗肝损伤、癌症药物的应用 | |
CN104341376B (zh) | 五指山参中一种新倍半萜醌类化合物及其制备方法和应用 | |
CN101880306B (zh) | 黄腊果皂苷类成分及其制备方法和应用 | |
CN102875518A (zh) | 京尼平甲醚、其制备方法及其医药用途 | |
CN103610682B (zh) | 3α-羟基-30-齐墩果-12,20(29)-二烯-28-酸的制备方法和在制备抗肿瘤药物中的应用 | |
CN101318946B (zh) | 化合物二聚兔耳风萜a及其制备方法和应用 | |
CN101284835B (zh) | 双倍半萜内酯类化合物及其制备方法和应用 | |
CN109942481A (zh) | 马齿苋中化合物Oleraisoindole A及其提取分离方法与应用 | |
CN101628863B (zh) | 一组从山莓叶中分离出的化合物、制备方法及其用途 | |
CN105418722B (zh) | 一种名为油茶皂苷c4和c5的五环三萜类化合物的制备方法 | |
CN107629104A (zh) | 三萜皂苷药物化合物及其制剂和应用 | |
CN106810551A (zh) | 两种新碳架生物碱化合物及其提取分离方法 | |
CN108948040B (zh) | 一种烟管头草中提取的吉玛烷型倍半萜化合物及其应用 | |
CN101284030B (zh) | 毛冬青药材、提取物或毛冬青制剂的质量控制方法 | |
CN103980198B (zh) | 生物碱Casuarinine H及其在制备治疗神经退行性疾病药物中的用途 | |
CN101565443A (zh) | 新冷杉三萜内酯类化合物及其制备方法和应用 | |
CN103694302B (zh) | 2α,3β-二羟基-30-齐墩果-12,20(29)-二烯-28-酸的制备方法和在制备抗肿瘤药物中的应用 | |
CN101318966B (zh) | 二聚倍半萜类化合物及其制备方法和应用 | |
CN110041386A (zh) | 特女贞苷的制备方法、特女贞苷及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20181113 Address after: Room 2-914, Academy Science and Technology Building, No. 1151 Road, Yan'an, Bengbu City, Anhui Province Patentee after: BENGBU YUESHENG TECHNOLOGY Co.,Ltd. Address before: 150076 138 Tongda street, Daoli District, Harbin, Heilongjiang Patentee before: HARBIN NINGSHENG TECHNOLOGY CO.,LTD. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240205 Address after: Unit 1510, No. 2, Riyuan Erli, Huli District, Xiamen City, Fujian Province, 361006 Patentee after: Xiamen jintekang Biotechnology Co.,Ltd. Country or region after: China Address before: Room 2-914, Academy Science and Technology Building, No. 1151 Road, Yan'an, Bengbu City, Anhui Province Patentee before: BENGBU YUESHENG TECHNOLOGY Co.,Ltd. Country or region before: China |
|
TR01 | Transfer of patent right |